NCT04882163 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04882163
Title	Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
Recruitment	Withdrawn
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Celgene
Indications	B-cell lymphoma primary mediastinal B-cell lymphoma diffuse large B-cell lymphoma follicular lymphoma
Therapies	Cisplatin + Dexamethasone + Gemcitabine + Iberdomide + Rituximab Lenalidomide + Tafasitamab-cxix Iberdomide + Polatuzumab vedotin-piiq + Rituximab Iberdomide + Tafasitamab-cxix Bendamustine + Polatuzumab vedotin-piiq + Rituximab
Age Groups:	adult \| senior
Covered Countries	USA \| GBR \| FRA \| ESP \| BEL \| AUT

Additional content available in CKB BOOST